Cannabidiol (CBD) Oral Solution for PWS: Phase 2 Clinical Trial Begins

cannabidiol-cbd-oral-solution-for-pws-phase-2-clinical-trial-beginsINSYS Therapeutics recently initiated a Phase 2 clinical trial of its cannabidiol (CBD) oral solution for evaluation of safety and efficacy in pediatric patients with Prader-Willi syndrome.

The INSYS study will measure the effect of the company’s propriety CBD oral solution on behavior related to hyperphagia. The study is enrolling 66 patients ages 8 – 17 years old at 10 clinical sites in the United States, with results expected in the fourth quarter of 2019. The first trial site is now open. Click here for more details

“While Prader-Willi syndrome presents a complex constellation of symptoms to address, our study will focus on one of the most challenging, hyperphagia,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “Our formulation of CBD has the potential to be an important addition to the limited range of treatment options for this condition.”

In December 2017, the FDA granted INSYS “Fast Track” designation for the company’s clinical development program in Prader-Willi syndrome. The purpose of FDA fast track designation is to aid in the development and expedite the review of drugs which show promise in treating a serious or life-threatening disease and address an unmet medical need. “FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome,” said Steve Sherman,

In addition to this Phase 2 clinical trial of CBD in Prader-Willi syndrome, INSYS has also recently started trials of CBD as an investigational treatment for infantile spasms (Phase 3) and childhood absence epilepsy (Phase 2).

Information on this study is available at

For updated information on PWS clinical trial opportunities and to sign up for a monthly PWS Clinical Trial Alert, visit our PWS Clinical Trials page.

PWS Clinical Trials 

Topics: News

Susan Hedstrom


Susan Hedstrom is the Executive Director for the Foundation for Prader-Willi Research. Passionate about finding treatments for PWS, Susan joined FPWR in 2009 shortly after her son, Jayden, was diagnosed with Prader-Willi Syndrome. Rather than accepting PWS as it has been defined, Susan has chosen to work with a team of pro-active and tireless individuals to accelerate PWS research in order to change the natural history of PWS. Inspired by her first FPWR conference and the team of researchers that were working to find answers for the syndrome, she hosted her first One SMALL Step walk in 2010 and began the development of the One SMALL Step walk program which now raises over $1.5 million a year for PWS research.

PWS Blog Subscribe